FDA Panel Teeters, But Keeps Bone Growth Stimulators Class III
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panel members said June 2 that the agency should continue to require clinical trials to ensure the safety and efficacy of medical devices that employ magnetic or electrical signals to help treat certain types of bone fractures and spinal disease